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Abstract: Narcolepsy is a lifelong sleep disorder characterized by a classic tetrad of excessive 
daytime sleepiness with irresistible sleep attacks, cataplexy (sudden bilateral loss of muscle 
tone), hypnagogic hallucination, and sleep paralysis. There are two distinct groups of patients, 
ie, those having narcolepsy with cataplexy and those having narcolepsy without cataplexy. 
Narcolepsy affects 0.05% of the population. It has a negative effect on the quality of life of its 
sufferers and can restrict them from certain careers and activities. There have been advances in 
the understanding of the pathogenesis of narcolepsy. It is thought that narcolepsy with cataplexy 
is secondary to loss of hypothalamic hypocretin neurons in those genetically predisposed to the 
disorder by possession of human leukocyte antigen DQB1*0602. The diagnostic criteria for 
narcolepsy are based on symptoms, laboratory sleep tests, and serum levels of hypocretin. There 
is no cure for narcolepsy, and the present mainstay of treatment is pharmacological treatment 
along with lifestyle changes. Some novel treatments are also being developed and tried. This 
article critically appraises the evidence for diagnosis and treatment of narcolepsy.
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Introduction
Narcolepsy is a debilitating lifelong rapid eye movement (REM) sleep disorder. It is 
characterized by the classic tetrad of excessive daytime sleepiness with irresistible 
sleep attacks, cataplexy (sudden bilateral loss of muscle tone), hypnagogic hallucina-
tion, and sleep paralysis.1 Other features include fragmented night sleep and automatic 
behavior, loss of concentration and memory, and blurry vision.2–5 The presentation is 
variable in terms of symptoms and intensity over time, and only about 10% of patients 
concurrently exhibit all components of the tetrad.6 There are two distinct groups of 
patients, ie, those having narcolepsy with cataplexy and those having narcolepsy 
without cataplexy.
It often coexists with other sleep disorders, like obstructive sleep apnea syndrome, 
periodic limb movements in sleep, REM sleep behavior disorder, and nocturnal eat-
ing disorder.7–12
Epidemiology
The prevalence of narcolepsy in European countries varies from 0.02% to 0.05%.13–15 It 
shows marked ethnic variation in prevalence rate, being 0.0002% in Israel and 0.16% 
in Japan.16,17 The varying prevalence rates may be as a result of varying disease defini-
tions, varying study designs, varying age group inclusion in studies, or an actual varying 
disease prevalence due to other factors.18,19 It has been suggested that the   differences in 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
507
REviEw
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/NDT.S23624Neuropsychiatric Disease and Treatment 2011:7
prevalence may be partly related to the association between 
narcolepsy and the prevalence of the human leukocyte anti-
gen (HLA) DQB1*0602 phenotype.14 The subgroup having 
narcolepsy without cataplexy may represent 10%–50% of 
the narcolepsy population.20 The estimated incidence rate 
is 0.74/100,000 per year for narcolepsy with cataplexy and 
1.37/100,000 per year for both narcolepsy with cataplexy and 
narcolepsy without cataplexy.21 The incidence rate is highest in 
the second decade, and the disorder is more common in men.21
Pathophysiology
Genetic and environmental basis
Although most cases are sporadic, there are definite cases 
with familial clustering. The risk of narcolepsy in first-degree 
relatives of patients is 10–40 times higher than in the general 
population.22 There is an environmental contribution as well, 
as shown by reported concordance rates of 25%–31% in 
monozygotic twins.23 The nature of possible environmental 
triggers is unknown. Nevertheless, the onset is frequently asso-
ciated with nonspecific environmental factors, such as head 
trauma, stroke, and change in sleep-wake cycle.23 Moreover, 
recent studies have shown an association with streptococcal 
infection,24,25 HIN1 vaccination or infection,26 and exposure 
to heavy metals, insecticides, and weed killers.27
HLA haplotype
More than 85% of patients having narcolepsy with cataplexy 
have HLA DQB1*0602, often in combination with HLA 
DR2 (DRB1*1501), while only half of patients having 
atypical, mild, or narcolepsy without cataplexy have HLA 
DQB1*0602.28 Other alleles of HLA also affect the predis-
position to narcolepsy with cataplexy.29,30 Occurrence of the 
HLA DQB*0602 allele is not limited to narcolepsy with 
cataplexy, and is found in 12%–38% of the general popula-
tion.23 Moreover, there are some rare patients with definite 
cataplexy who do not have HLA DQB1.31 Overall, the poor 
discriminatory ability of HLA typing limits its usefulness 
and makes it unsuitable as a routine diagnostic test.
Hypocretins
Hypocretins 1 and 2, also called orexins A and B, are two 
dorsolateral hypothalamic neuropeptides that function in reg-
ulating sleep-wake cycles, food intake, and pleasure-seeking 
behavior.32 Amongst the areas of the brain that the neurons 
producing hypocretins project to are the locus ceruleus, 
tuberomammillary nucleus, raphe nucleus, and ventral 
  tegmental areas.32 These areas correspond to   norepinephrine, 
histamine, serotonin, and dopamine secretion, respectively. 
Deficiency of hypocretin could lead to malfunctioning of 
these systems and therefore abnormalities of REM sleep 
and excessive daytime sleepiness.33 Hypocretin neurons 
also project to other areas of the hypothalamus, olfactory 
bulb, cerebral cortex, and thalamus.34,35 The evidence for 
hypocretin deficiency is as follows.
In 1979, Foutz et al showed that narcolepsy was inher-
ited in a single autosomal recessive pattern in Doberman 
  Pinschers.36 Lin et al later identified this as a mutated 
hypocretin receptor 2 gene.37 One of the earliest reports of 
hypocretin deficiency in narcolepsy with cataplexy was that 
of Nishino et al in 2000. Their study showed that whilst seven 
of nine patients having narcolepsy with cataplexy had no 
detectable hypocretin, the neuropeptides were detectable in 
all their eight matched controls.38 Further studies have sup-
ported hypocretin neurotransmission deficiency in narcolepsy 
with cataplexy.31,39,40
It was subsequently found that, unlike in animals, hypo-
cretin deficiency in humans having narcolepsy with cataplexy 
was not due to mutation in hypocretin genes but rather 
secondary to loss of hypocretin neurons in the dorsolateral 
hypothalamus.39,40 Peyron et al found only one patient (an 
atypical case with onset of narcolepsy with cataplexy at the 
age of 6 months) with hypocretin mutation among 74 patients 
screened for mutation. She also found global loss of hypo-
cretin neurons in the brains of six deceased patients who 
had suffered from narcolepsy with cataplexy.40 Furthermore, 
Thannickal et al found the number of hypocretin neurons to 
be reduced by 85% to 95% in association with evidence of 
gliosis.39 These studies collectively suggested that the loss 
of hypocretin neurons in patients having narcolepsy with 
cataplexy might be inflammatory in nature.
Autoimmunity
The combination of HLA antigens, hypocretin deficiency, 
hypocretin neuron loss, the rarity of hypocretin gene muta-
tions, and onset in the second decade of life points strongly 
towards an autoimmune etiology.38–40 Initial efforts at isolat-
ing an autoantibody proved unsuccessful.41,42 However, there 
was indirect evidence for an autoimmune nature of narco-
lepsy, such as its temporary response to steroids.42,43 Recently, 
methods have been developed to demonstrate the presence 
of autoantibodies. There has been a demonstration of an 
autoantibody which disrupts colonic migrating motor com-
plexes.44 A Tribbles homolog 2 (Trib2) transcript (an autoan-
tigen in autoimmune uveitis45) has been shown to be enriched 
in hypocretin neurons from genetically engineered mice.46 
Enzyme-linked immunosorbent analysis was used in turn to 
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show that sera from patients having narcolepsy with cataplexy 
had higher Trib2-specific antibody titers compared with 
those in normal controls or patients with other neurological 
diseases.46 Moreover, serum from a patient having narcolepsy 
with cataplexy showed specific immunoreactivity with over 
86% of hypocretin neurons in the mouse hypothalamus.46 This 
finding was replicated in another study that found autoanti-
bodies against Trib2 in 26.1% of patients having narcolepsy 
with cataplexy compared with 2.3% of healthy controls.47 
Thus, a subgroup of patients having narcolepsy with cata-
plexy might be suffering from anti-Trib2 autoimmune dis-
order. Furthermore, another study has found an association 
between narcolepsy with cataplexy and polymorphism in 
the T cell receptor alpha genetic locus (encoding the major 
receptor for HLA peptide presentation in any disease) in three 
ethnic groups compared with normal matched controls.48
Further support for an autoimmune etiology comes from 
cytokine studies showing higher interleukin-6, tumor necro-
sis factor-α, and tumor necrosis factor receptor p75 levels 
in patients having narcolepsy with cataplexy.49–51 However, 
Fontana et al have suggested that immune-mediated destruc-
tion of hypocretin cells might occur independent of T cells.52 
Moreover, a lack of hypocretin is not specific to narcolepsy 
with cataplexy. It has also been reported in patients with 
Guillain–Barré and Miller Fisher syndromes.53,54
Loss of hypocretin-producing neurons definitely causes 
narcolepsy with cataplexy.31,39,40,55 Other neurological insults, 
lesions of the hypothalamus or nearby structures, and global 
traumatic, vascular, or inflammatory insults to the brain could 
also cause narcolepsy.56–58 All this could affect the levels of 
hypocretin either transiently or permanently (see Table 1).55
Diagnosis
The first step in the diagnosis of narcolepsy is history-taking 
from the patient and from partners, relatives, and friends. Apart 
from atonia and areflexia in patients having active cataplexy, 
the physical examination should be normal.5 The current 
International Classification of Sleep Disorders (ICSD-2) 
definition for narcolepsy is shown in Table 2.59 It is based on 
history, polysomnography, multiple sleep latency tests (MSLT), 
and measurement of hypocretin levels in cerebrospinal fluid. 
It classifies narcolepsy into three types (see Table 2). Exces-
sive daytime sleepiness is the most constant feature of narco-
lepsy6 and measuring it accurately is important. There are a 
number of subjective and objective scales to measure this.
Subjective measures of excessive  
daytime sleepiness
The main advantages of subjective measures of excessive 
daytime sleepiness are that they are less cumbersome, less 
time-consuming, and less expensive compared with objective 
tests.60 Their main drawback is their inconsistent reliability 
in correlating with objective tests.61
The Epworth Sleepiness scale was developed by   Murray 
Johns in Australia in 1991 and was validated using 150 
consecutive clinic patients with a range of sleep disor-
ders and 30 hospital worker controls.60 Thus, the study 
sample was from neither the normal population nor from 
the same   population. The Epworth Sleepiness scale is a 
self-  administered questionnaire in which patients rate their 
likelihood of   falling asleep in eight different life situations. 
Table  2  The  International  Classification  of  Sleep  Disorders  for 
narcolepsy59
Narcolepsy with cataplexy
Excessive daytime sleepiness almost daily for at least 3 months
Definite history of cataplexy
Diagnosis should be confirmed, whenever possible, by one of the 
following:
Polysomnographya and MSLTb; mean sleep latency should be #8 minutes 
and at least 2 SOREMSc
CSFd hypocretin level #110 pg/mL or 1/3 of mean normal controls
Hypersomnia is not better explained by another disorder or medication
Narcolepsy without cataplexy
Excessive daytime sleepiness almost daily for at least 3 months
Definite cataplexy is not present
Diagnosis must be confirmed by polysomnography or MSLT
Mean sleep latency should be #8 minutes and $2 SOREMs
Hypersomnia is not better explained by another disorder or medication
Secondary narcolepsy (narcolepsy due to medical condition)
Excessive daytime sleepiness almost daily for at least 3 months
One of the following is present: definite history of cataplexy; if cataplexy 
is not present, diagnosis must be confirmed by polysomnography and 
MSLT; mean sleep latency should be #8 minutes and at least 2 SOREMS; 
CSF hypocretin level #110 pg/mL
Underlying medical or neurological condition accounts for the sleepiness
Hypersomnia is not better explained by another disorder or medication
Abbreviations: MSLT, Multiple Sleep Latency Time; SOREM, sleep onset REM; 
CSF, cerebrospinal fluid.
Note: Reproduced with permission from American Academy of Sleep Medicine. 
The International Classification of Sleep Disorders, Diagnostic and Coding Manual. 2nd ed. 
westchester, iL: American Academy of Sleep Medicine; 2005.
Table 1 Primary and secondary etiologies of narcolepsy
Hypocretin deficiency
Hypothalamic lesions
inherited disorders eg Neimann–Pick disease type C
Brain tumors
Craniocerebral trauma 
Cerebrovascular disorders
Encephalomyelitis
Neurodegenerative diseases
Demyelinating disorders
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Each situation is scored from 0 to 3 and the total score varies 
from 0 to 24. It has been validated in different clinical situa-
tions and languages.62–65 It correlates best with the objective 
tests in comparison with other subjective tests.60
Other subjective measures include the Stanford Sleepi-
ness scale which rates excessive daytime sleepiness accord-
ing to the subjects’ perception of their sleepiness/alertness 
at a particular time,60 and the visual analog scale, with which 
subjects indicate their levels of sleepiness along a continu-
ous line between two points. These two tests only measure 
sleepiness at a particular time rather than general daytime 
sleepiness. Thus, their main application is in research rather 
than in the clinic, when they can only be used for point-in-
time estimation of sleepiness.61 Based on the above consid-
erations, our recommended clinical subjective measure is the 
Epworth Sleepiness scale.
Objective measures of excessive  
daytime sleepiness
Polysomnography is a method which is usually performed 
overnight in a sleep laboratory before MSLT. Data such 
as breathing, movement, time spent asleep, heart rate, and 
electroencephalography are obtained.18,66,67 Patients may 
have audio and video monitoring that could reveal snoring, 
sleep talking, movement, and complex behavior during 
sleep.18 Thus, it can reveal the etiology of excessive daytime 
sleepiness and other sleep pathologies. However, perform-
ing polysomnography itself can cause disruption to sleep, 
potentially affecting MSLT on the following day.18 Thus, it 
is recommended that at least 6 hours of sleep is recorded on 
the night before MSLT.67
MSLT is the accepted standard objective measure for 
excessive daytime sleepiness and has good inter-rater and 
intrarater reliability.18,60,66 It consists of five scheduled naps 
during the day, each lasting 20 minutes and 2 hours apart. 
Ideally, it is carried out under conditions that best help 
patients to fall asleep, eg, appropriate temperature and 
limited stimulation. Patients are required to stay awake 
between each nap opportunity. During the tests, physiologi-
cal data are gathered, such as time taken to fall asleep and 
the presence or absence of REM sleep.18 When REM sleep 
occurred within 15 minutes of onset, it is termed sleep-
onset REM sleep (SOREM). It is common in narcolepsy 
but rare in normal individuals.18 Patients should spend at 
least 8 hours in bed per night in the preceding week in order 
to avoid erroneous results.68 This can be confirmed using 
a documented sleep log or, more objectively, by the use of 
wrist actigraphy,69 which entails wearing a motion-sensitive 
device that uses lack of movement as a surrogate for the 
period spent asleep.68
The current ICSD-2 MSLT criteria shown in Table 2 might 
not be specific for narcolepsy, as shown by Allen70 who car-
ried out polysomnography and MSLT in 289 normal males 
and 267 normal females, and analyzed subject variables 
such as age, gender, body mass index, and HLA typing 
against their results on MSLT. Allen found that 4.2% and 
0.4% of males and females, respectively, had two SOREMS 
and an excessive daytime sleepiness score of $11 on the 
Epworth Sleepiness scale (ICSD-2 criteria for narcolepsy 
without cataplexy, see Table 2). Furthermore, shift work, 
use of non-REM-suppressing antidepressants, a positive 
HLA DQB1*0602, decreased oxygen saturation, and a sleep 
diary showing a 1-hour decrease in sleep the night before 
polysomnography, are all related to two or more SOREMs. 
Therefore, several other factors and sleep disorders could 
result in two SOREMs, and two SOREMs are not as specific 
for narcolepsy as suggested by ICSD-2 criteria.
Moreover, a recent case series showed five patients diag-
nosed as having narcolepsy with cataplexy based on history 
alone (consistent with ICSD-2 criteria) but whose diagnoses 
were later found not to be corroborated by MSLT, and all 
were HLADQB1*0602 negative.71 Thus, the diagnosis of 
narcolepsy irrespective of whether it is narcolepsy with 
cataplexy or narcolepsy without cataplexy should be based 
both on clinical symptoms and MSLT, and reliance on either 
alone may be insufficient.
The maintenance of wakefulness test is a variant of the 
MSLT, and measures the ability to stay awake. It consists of 
4–5 trials of trying to remain awake while in the recumbent 
position in a dark room. This is repeated every 2 hours. Each 
trial is terminated if no sleep occurs after 40 minutes.45 It 
is subject to the same caveats as the MSLT.60 It has been 
found to measure alertness rather than sleepiness.72 Thus, it 
is used to measure the ability to stay awake in individuals 
with jobs that require a high level of alertness and also to 
assess response to treatment by those with excessive daytime 
sleepiness in pharmacological trials,61 rather than to make 
a diagnosis. The correlations between the Epworth Sleepi-
ness scale, MSLT, and maintenance of wakefulness test are 
generally not impressive.61,73
Laboratory testing for HLA typing adds little to the 
diagnostic evaluation because its sensitivity is highest 
in patients having narcolepsy with cataplexy, a group in 
which additional diagnosis is rarely necessary.18,19,28,31 
Testing for hypocretin suffers from the same problem. In 
addition, it needs a lumbar puncture, which is an invasive 
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procedure with potential   complications. Nevertheless, 
hypocretin   measurement should be considered in the fol-
lowing   situations: following an equivocal MSLT result; 
in patients who cannot follow the instructions for MSLT; 
individuals who are unable to stop medications that could 
affect the result of MSLT; those with complex psychiatric, 
neurological, or medical disorders that could compromise 
the result of MSLT; in the patient who gives an excel-
lent history of narcolepsy with cataplexy but who has 
normal polysomnography and MSLT. In these patients, a 
hypocretin-1 level below 110 pg/mL in cerebrospinal fluid 
is highly indicative of narcolepsy, but a higher level does 
not necessarily exclude the diagnosis.55
In terms of neuroimaging, magnetic resonance studies 
are presently inconclusive in their findings, while magnetic 
resonance spectroscopy has revealed abnormal metabolism 
in the hypothalamus. Functional neuroimaging has revealed 
hypoperfusion and hypermetabolism in the hypothalamus, 
limbic cortex, and cerebrum.45,74–81 Overall, neuroimaging is 
not useful in the diagnosis of narcolepsy.
Differential diagnoses
•	 Sleep deprivation, sleep apnea, idiopathic hypersomnia, 
recurrent hypersomnia (Kleine–Levin syndrome), restless 
legs syndrome, and periodic limb movement disorder.82
•	 Neurological conditions commonly associated with 
sleepiness and REM sleep behavioral disorder, eg, 
  Parkinson’s disease, Alzheimer’s disease, and other neu-
rodegenerative conditions, including multiple sclerosis, 
stroke, epilepsy, neuromuscular disorders, and structural 
brain disorders (bithalamic or bicortical lesions affecting 
midline projecting systems).82–84
•	 Medical conditions commonly associated with sleepiness, 
such as respiratory disorders (eg, chronic obstructive 
pulmonary disease and asthma), cardiac disorders (eg, 
congestive heart failure), renal disorders (eg, chronic 
renal failure), rheumatologic disorders (eg, arthritis), 
inflammatory disorders (eg, lupus), hepatic disorders 
(eg, liver failure), and malignancy.82
•	 Major psychiatric disorders sharing symptoms of func-
tional impairment, insomnia, and hypersomnia with 
narcolepsy;85 reduced REM latency is common to major 
episodes of depression and narcolepsy;4,86,87 REM sleep-
related disorders in narcolepsy share some psychotic 
features with schizophrenia, eg, hypnagogic/hypnopom-
pic hallucination;88–90 some features of narcolepsy, such 
as sleep paralysis and sleep behavior disorder, could be 
misinterpreted as psychosis.91
•	 Stimulants used in the treatment of narcolepsy can give 
rise to psychotic symptoms.92
•	 Differences between the core symptoms of psychosis and 
symptoms of narcolepsy have been elaborated elsewhere93 
in a study comparing 148 narcolepsy patients, 21 schizo-
phrenic patients, and 128 healthy subjects, which found 
that episodes of hallucination in narcolepsy were sleep-
related and posture-related, and more likely to be visual and 
kinetic (83% and 71% in narcolepsy, respectively, compared 
with 29% and 5% in schizophrenia);93 the drawback of 
the study included discordant sample sizes for the groups, 
and the groups were also from different populations.
•	 In children, narcolepsy may present with only excessive 
daytime sleepiness, and the behavioral problem associated 
with excessive daytime sleepiness might be misdiagnosed 
as ADHD.94
•	 Malingering
•	 Cataplexy has been misdiagnosed as epilepsy or recurrent 
syncope.95–97
Treatment
Excessive daytime sleepiness and sleep 
attacks
Conventional treatments are essentially symptomatic, given 
that no cure has been found for narcolepsy. American Acad-
emy of Sleep Medicine classification of the levels of evidence 
that the authors follow in this paper are shown in Table 3.98
There is no randomized controlled trial to support the 
efficacy of nonpharmacological therapy. There is Level III 
evidence from a nonblinded controlled study that taking naps 
reduces excessive daytime sleepiness both subjectively and 
objectively,99 while hypnotherapy has only Level IV evi-
dence from a case series.100 Furthermore, there is Level IV 
evidence from an open-label study that a low-carbohydrate, 
high-protein diet can improve wakefulness.101 Overall, 
Table  3  Oxford  Centre  evidence-based  medicine  levels  of 
evidence98
Evidence level study design or description
   I. Randomized controlled trial with narrow confidence intervals
  II.   Randomized trials without narrow confidence intervals, or with 
methodological problems, or cohort studies
 iii.   Nonrandomized concurrently controlled studies or case-control 
studies
iv.   Case-control or cohort studies with methodological problems, or 
case series
 v. Expert opinion, or studies based on physiology or bench research
Note:  Abbreviated  with  permission  from  Centre  for  Evidence-based  Medicine. 
Levels of evidence 2009 [web page on the internet]. Oxford: Centre for Evidence-
based Medicine; 2009 [updated April 15, 2011]. Available from: http://www.cebm.
net/index.aspx?o=1025. Accessed April 20, 2011.
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  nonpharmacological therapies are not adequate alone as 
primary therapy for narcolepsy. According to an American 
Academy of Sleep Medicine report: “Scheduled naps can be 
beneficial to combat sleepiness but seldom suffice as primary 
therapy for narcolepsy.”102
Pharmacological therapy is the mainstay of treatment for 
excessive daytime sleepiness. There is only Level III and IV 
evidence of efficacy from trials using earlier medications. The 
earliest medication used in the treatment of narcolepsy was 
caffeine, but its cardiovascular side effects prohibited its use 
at higher doses.103 Other treatments included insulin-induced 
hypoglycemia (reported in 1952)104 and trazodone used to 
supplement methylphenidate.105 Both were case reports 
that led to temporary improvement. Other older treatments 
include mazindol, which was studied in a nonrandomized 
controlled trial with a short follow-up,106 and propranolol, 
which was found to be effective in a case report107 but not 
in an open-label study.108 Overall, these earlier medications 
are no longer used routinely in the treatment of narcolepsy.
Ritanserin is a serotonin antagonist with Level II evidence 
from two studies. One study demonstrated an improvement 
in subjective daytime sleepiness but not in sleep latency 
on MSLT when ritanserin 5 mg/day was added to usual 
medication in 28 patients.109 The second study compared 
ritanserin 5 mg and 10 mg with placebo in 134 patients, and 
did not find improvement in any of the objective measures, 
but did report an improvement in subjective sleep quality.110 
According to an American Academy of Sleep Medicine 
report: “Ritanserin may be effective treatment of daytime 
sleepiness due to narcolepsy.”102 Its most appropriate use is 
as an add-on medication.
Selegiline, a monoamine oxidase type B inhibitor, has a 
Level II study that demonstrated its efficacy for excessive 
daytime sleepiness and cataplexy.111 The American Academy 
of Sleep Medicine report has expressed some reservations 
about its use as the preferred initial choice for treatment of 
excessive daytime sleepiness,102 on account of its potential 
for drug and diet interactions.102
Traditional stimulants have been in use since the 1930s, 
initially caffeine and ephedrine, then amphetamines, 
methamphetamine, and dexamphetamine, and thereafter, 
their derivatives pemoline briefly and methylphenidate 
later.33,103,112 At low doses, stimulants release dopamine and 
noradrenaline through reversal of action of their presynaptic 
transporters. At higher doses, amphetamine inhibits vesicu-
lar monoamine transporter 2.113 The side effects of stimulants 
include irritability, headache, nervousness, palpitations, 
insomnia, and less often, orofacial   dyskinesia, anorexia, 
nausea, excessive sweating, psychosis, and myocardial 
infarction.113–115   Tolerance may develop in up to one-third 
of patients, and these have a potential for addiction.113 There 
is limited evidence to support their use. The only Level III 
evidence available for the efficacy of traditional stimulants 
was provided by Mitler et al116 who compared eight patients 
with narcolepsy and eight healthy matched controls. The 
patients received 0 mg, 20 mg, or 40–60 mg, while the con-
trols received 0 mg, 5 mg, or 10 mg of methamphetamine. 
MSLT sleep latency increased in both groups, from 4.3 to 
9.3 minutes in patients and from 10.4 to 17.1 minutes in 
controls.
Pemoline selectively blocks dopamine reuptake. It has 
the potential to cause fatal hepatotoxicity.113 On account of 
this, it has been withdrawn from the market and is no longer 
recommended.82
Methylphenidate, an N-methyl derivative of amphet-
amine, has a shorter half-life, milder side effects, and low 
abuse potential.33 It has Level II and Level IV evidence for 
its use. A nonrandomized controlled study compared the 
response of narcoleptic patients allocated to four treatment 
groups (methylphenidate, pemoline, protriptyline, and 
dextroamphetamine) and one placebo group. Each group 
had three dose regimens. Improvement in the maintenance 
of wakefulness test was used as the objective measure. All 
doses of methylphenidate and dextroamphetamine were 
efficacious, while doses of pemoline ,112.5 mg and doses 
of protriptyline up to 60 mg/day were not efficacious.117 
Honda et al reported a dose-related improvement in 92% of 
106 patients treated with methylphenidate (50 patients had 
more than 5 years of treatment).118 However, the improve-
ment might not have been solely due to methylphenidate 
because many of the patients were also receiving concurrent 
hypnotics or tricyclic antidepressants. Stimulants including 
amphetamine, methamphetamine, dextroamphetamine, and 
methylphenidate are effective for the treatment of daytime 
sleepiness due to narcolepsy.102 However, treatment should 
be individualized, and patients should be closely followed 
up to ensure efficacy and detection of side effects.102
Modafinil and its R enantiomer, armodafinil, are wake-
promoting agents that have an additional phenyl group and an 
amide instead of an amine group in their chemical structure 
when compared with amphetamine.113 Although the mecha-
nism of action of modafinil is unclear, it is believed to work 
through the dopaminergic, adrenergic, and histaminergic 
systems.33 Recently, a functional neuroimaging study has 
shown that modafinil increases extracellular levels of dop-
amine in the human brain.119 Furthermore, another study has 
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shown that modafinil indirectly inhibits gamma aminobutyric 
acid by activating potassium ATP channels in animals.120 Its 
side effects include headache, dry mouth, insomnia, nausea, 
vomiting, anxiety, tachycardia, palpitation, chest pain, and 
dermatological reactions, like Stevens–Johnson syndrome.18 
Unlike the stimulants, the efficacy of modafinil has been 
evaluated by double-blind, placebo-controlled, randomized 
trials (Level I evidence).121–123 These trials are summarized 
in Table 4.
Furthermore, recent crossover, randomized, controlled 
trials have shown more sustained wakefulness with higher 
doses and superior results with a split dose of modafinil.124,125 
This occurred when the maintenance of wakefulness test 
was performed in the evenings rather than 1 hour after 
administration of medication, as performed in the ran-
domized controlled trials shown in Table 4. Modafinil 
does not seem to impair night-time sleep as shown by a 
nonrandomized control study (Level III evidence), which 
compared the effect of modafinil on night-time sleep 
with that of dextroamphetamine in healthy volunteers. 
The subjects received 100 mg and 200 mg of modafinil 
and 10 mg and 20 mg of dextroamphetamine in a crossover 
design. Dextroamphetamine reduced total night sleep time 
and REM sleep time, but these were unchanged in placebo 
and modafinil patients.126 An open-label study (Level IV 
evidence) is suggestive of lack of development of toler-
ance to modafinil. In this study, the investigators followed 
up patients with narcolepsy treated with modafinil for 
40 weeks. The subjects demonstrated sustained improve-
ment in excessive daytime sleepiness and quality of life 
for the 40-week duration of the trial.127
Armodafinil 150 mg and 250 mg has also been shown 
by a randomized controlled trial to lead to an improvement 
in both morning and late maintenance of wakefulness test, 
sleep latency, and Clinical Global Impression of Change 
score when compared with placebo.128 However, there are no 
direct comparisons of armodafinil and modafinil. Modafinil 
and armodafinil are effective for excessive daytime sleepi-
ness, and are recommended for the treatment of excessive 
daytime sleepiness due to narcolepsy.102,129
Table 4 Double-blind randomized controlled studies of modafinil
Study Placebo  
group
Treatment  
group 1
Treatment 
group 2
Outcome  
measures
Duration Results Drawbacks
US 18-center  
study121
n = 92 Modafinil 
200 mg 
n = 96
Modafinil 
400 mg as  
a single dose 
n = 95
MwT, MSLT,  
ESS, CGi-S
0, 3, 6,  
9 weeks
MwT, MSLT, CGi-S,  
ESS, significantly reduced  
in the 2 treatment  
groups compared with  
placebo but no significant  
difference between the  
2 treatment groups  
(P , 0.001)
Drug company  
sponsored 
Short follow-up
US 21-center  
study122
n = 93 Modafinil 
200 mg 
n = 89
Modafinil 
400 mg as  
a single dose 
n = 89
MwT, 
MSLT, ESS,  
CGi-S
9 weeks MwT, MSLT, CGi-S, ESS,  
significantly improved  
in the 2 treatment  
groups compared with  
placebo but no significant  
difference between the  
2 treatment groups  
(P , 0.001). Dropout  
rate 6%, return of EDS  
after discontinuation  
of modafinil but no  
withdrawal effect
Drug company  
sponsored 
Short follow-up 
MwT tested  
1 hour after
Canadian  
nine-center  
crossover  
study123
Each of 75 patients 
received in order: 
Placebo first 2-week
Second 
2-week period 
200 mg of  
modafinil
Third 
2-week 
period 
200 mg twice  
daily of  
modafinil
MwT, 
ESS, 
patient sleep  
diary
6 weeks MwT and ESS  
significantly improved. 
No significant difference  
between the doses,  
5% dropout rate, well  
tolerated by patients
Drug company  
sponsored 
No washout  
periods 
MwT tested  
1 hour after  
administering  
medication
Abbreviations: EDS, excessive daytime sleepiness; MwT, maintenance of wakefulness test; MSLT, multiple sleep latency time; ESS, Epworth Sleepiness scale; CGi-S, Clinical 
Global impression of Change.
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Cataplexy, sleep paralysis, and hypnagogic 
hallucination
A report of the effectiveness of imipramine in the treat-
ment of cataplexy in 1960 led to widespread use of tricyclic 
antidepressants.130 Their effect could be due to an ability 
to inhibit the reuptake of catecholamines, increase muscle 
tone, or suppress REM sleep.131–133 Side effects include nau-
sea, anorexia, dry mouth, urinary retention, constipation, 
and sexual dysfunction. Rebound cataplexy, which may be 
severe and prolonged (status cataplecticus), may occur on 
sudden withdrawal from tricyclic antidepressants.33 There 
are only case reports and case series (level IV evidence) for 
their efficacy.134
Selective serotonin reuptake inhibitors inhibit presyn-
aptic serotonin reuptake and also nocturnal REM sleep. 
  Femoxetine has Level II evidence for treating cataplexy from 
a crossover, placebo-controlled study involving 10 patients. 
Only case series and reports (Level IV evidence) are available 
for other selective serotonin reuptake inhibitors.135,136
Other antidepressants, including noradrenergic reuptake 
inhibitors, such as venlafaxine, duloxetine, reboxetine, and 
viloxazine, are being used.137,138 There is a Level III single-
blind, crossover, placebo-controlled study of viloxazine 
involving 23 patients, with one dropout.139 There are only 
case series (Level V evidence) available for venlafaxine and 
duloxetine.137,140
Overall, there is a lack of good evidence for the use of 
antidepressants in treating cataplexy. Nevertheless, according 
to the American Academy of Sleep Medicine report: “Based 
on consensus and clinical experience ... they may be an 
effective treatment for cataplexy, hypnagogic hallucination 
and sleep paralysis.”102
Cataplexy and excessive daytime 
sleepiness
Gamma hydroxybutyrate, marketed as sodium oxybate, is a 
natural metabolite of gamma aminobutyrate (GABA), and 
is a GABAB receptor agonist at a pharmacological dose.18 
Its exact mechanism of action is not known, but it increases 
slow wave sleep, decreases arousals, and has a variable 
effect on latency and amount of REM sleep.141,142 Level I 
evidence for the efficacy of gamma hydroxybutyrate was 
provided by three multicenter, randomized, double-blind, 
placebo-controlled studies of the short-term and long-term 
efficacy of gamma hydroxybutyrate.143–145 In the first trial, 136 
narcolepsy patients with 3–249 cataplexy attacks weekly were 
enrolled to receive 3.6 g or 9 g of gamma hydroxybutyrate 
or placebo taken in equal divided doses on retiring to bed 
and 2.5–4.0 hours later for 4 weeks. The primary measure of 
efficacy was a change in baseline weekly cataplectic attacks, 
while secondary measures included excessive daytime 
sleepiness using the Epworth Sleepiness scale, inadvertent 
daytime naps, and night-time awakenings. In total, 88% of 
participants completed the trials. Weekly cataplectic attacks 
started to decrease at a 6 g dose and became significant at a 
9 g dose, and excessive daytime sleepiness was reduced at all 
doses, becoming significant at the 9 g dose. The frequency of 
inadvertent daytime naps and night-time awakenings reduced 
at all doses, becoming significant at the 9 g dose.143 The 
second trial included 55 patients stabilized on nightly doses 
of gamma hydroxybutyrate for at least 6 months. They were 
then randomized into two arms, ie, one abruptly changing to 
placebo and the other continuing on gamma hydroxybutyrate 
for 2 weeks. Cataplexy gradually returned in those patients 
that were changed onto placebo over 2 weeks, but none of the 
patients suffered withdrawal symptoms.144 This suggests lack 
of development of tolerance to gamma hydroxybutyrate.
The third trial compared the effect of nightly gamma 
hydroxybutyrate 4.5 g, 6 g, or 9 g with placebo in 228 adult 
patients over 8 weeks.145 The patients showed a significant 
dose-related increase in duration of stage 3 and 4 sleep, 
reaching a median duration of 52.5 minutes in patients 
receiving gamma hydroxybutyrate 9 g nightly. Frequency of 
nocturnal awakening and stage 1 sleep were each significantly 
decreased at nightly doses of gamma hydroxybutyrate 6 g 
and 9 g. This study showed that gamma hydroxybutyrate 
decreased the sleep disruption and fragmentation that are 
usually associated with narcolepsy. Moreover, two Level IV 
(open-label) studies have demonstrated the tolerability and 
sustained efficacy of gamma hydroxybutyrate.146,147
From the gamma hydroxybutyrate trials, common side 
effects have included dizziness, headache, nausea, pain, som-
nolence, sleep disorder, confusion, infection, vomiting, and 
enuresis.33 Illicit use in high doses could result in addiction 
and withdrawal. Sudden deaths have been reported in patients 
who have risk factors for obstructive sleep apnea.148 Overall, 
gamma hydroxybutyrate is effective, and is recommended 
for treatment of cataplexy, excessive daytime sleepiness, and 
disrupted sleep due to narcolepsy.102
Future treatments
Introduction of hypocretin-1 into the cerebral ventricular system 
was found to be useful in mice but not in   hypocretin-2 mutated 
dogs.149 Intranasal administration is promising, as well as 
transplantation of neonatal hypothalamic stem cells into 
the brainstem.149,150 Narcolepsy with cataplexy is strongly 
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suspected to be an autoimmune disorder. However, attempts 
to modify immune processes, including use of steroids, 
plasmapheresis, and intravenous immunoglobulin, have been 
met with limited and short-term success.151–153 Histamine 
3 receptors regulate the release of histamine. Antagonism of 
the histamine 3 receptor enhances wakefulness, while stimula-
tion causes sedation.154 Histamine 3 receptor antagonists have 
been shown to be effective in canines and mice.155,156 Other 
promising novel treatments include thyrotrophin-releasing 
hormone and the nicotine patch.156,157
Conclusion
Our understanding of the pathogenesis of narcolepsy contin-
ues to advance, with substantial evidence that autoimmune 
loss of hypocretin neurons is the main cause of narcolepsy 
with cataplexy. The standardized criteria for narcolepsy and 
diagnostic measures are generally accepted, but might need 
to be reviewed in the future. There is established pharma-
cotherapy for symptomatic treatment of narcolepsy. Future 
treatment modalities, such as hypocretin analogs and hista-
mine receptor antagonists, should aim to tackle the cause of 
narcolepsy.
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